Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BURAN Study of Buparlisib in Combination with Paclitaxel vs Paclitaxel Alone in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
2019-000790-23Phase 3Active
- Sponsor
- Adlai Nortye
- Start
- Feb 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of buparlisib in head and neck squamous cell carcinoma (HNSCC) (2 arms), sponsored by Adlai Nortye. Primary endpoint: Overall survival (OS). Started Feb 2021; status: active.
02
Drugs
buparlisib
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on 2019-000790-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-000790-23.